These provided direct evidence that additional blockade of PD-1 hindered tumor from breaking away from an anti-CTLA-4 inhibitor monotherapy and additional blockade of PD-1 handicapped tumor from getting rid of a-CTLA-4 monotherapy via protecting immunity by both T-cell-dependent, and natural killer (NK)/natural killer T (NKT) cell-independent fashions (27). The gene discussed is CTLA4; the disease is neoplasm.